Insider Selling: Oncology Institute (NASDAQ:TOI) Insider Sells 23,451 Shares of Stock

The Oncology Institute, Inc. (NASDAQ:TOI) insider Yale Podnos sold 23,451 shares of Oncology Institute stock in a transaction on Monday, June 8th. The stock was sold at an average price of $5.38, for a total value of $126,166.38. Following the transaction, the insider directly owned 259,527 shares of the company’s stock, valued at approximately $1,396,255.26. This represents a 8.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oncology Institute Price Performance

TOI traded down $0.11 during trading on Tuesday, reaching $4.96. 1,749,711 shares of the stock were exchanged, compared to its average volume of 1,864,511. The company has a market capitalization of $490.25 million, a price-to-earnings ratio of -13.41 and a beta of 0.37. The Oncology Institute, Inc. has a 1 year low of $2.02 and a 1 year high of $5.57. The business’s 50 day moving average price is $3.86 and its two-hundred day moving average price is $3.41.

Oncology Institute (NASDAQ:TOI) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.05. The firm had revenue of $147.44 million for the quarter, compared to analyst estimates of $142.10 million. On average, analysts anticipate that The Oncology Institute, Inc. will post -0.17 EPS for the current year.

Institutional Investors Weigh In On Oncology Institute

Several large investors have recently made changes to their positions in TOI. Kestra Advisory Services LLC acquired a new position in shares of Oncology Institute during the 4th quarter valued at $31,000. Pekin Hardy Strauss Inc. purchased a new position in Oncology Institute in the fourth quarter valued at about $36,000. R Squared Ltd purchased a new position in Oncology Institute in the fourth quarter valued at about $41,000. Prelude Capital Management LLC acquired a new position in shares of Oncology Institute during the third quarter worth about $41,000. Finally, BNP Paribas Financial Markets lifted its stake in shares of Oncology Institute by 141.0% during the third quarter. BNP Paribas Financial Markets now owns 12,119 shares of the company’s stock worth $42,000 after purchasing an additional 7,091 shares in the last quarter. Institutional investors and hedge funds own 36.86% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on TOI. Needham & Company LLC reaffirmed a “buy” rating and issued a $5.00 price target on shares of Oncology Institute in a report on Monday, March 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Oncology Institute in a research report on Monday, April 20th. BTIG Research upped their target price on Oncology Institute from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Monday. Finally, B. Riley Financial raised their price objective on Oncology Institute from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $7.25.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.